Cell therapies for inflammatory bowel diseases

References

• Cosnes J, Nion-Larmurier I, Beaugerie L, Afchain P, Tiret E, Gendre JP. Impact of the increasing use of immunosuppressants in Crohn’s disease on the need for intestinal surgery. Gut54(2), 237–241 (2005).
   PubMed Web of Science ®Google Scholar
• Chamberlain G, Fox J, Ashton B, Middleton J. Concise review, mesenchymal stem cells, their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells25(11), 2739–2749 (2007).
   PubMed Web of Science ®Google Scholar
• Kapoor S, Wilson AG, Sharrack B et al. Haemopoietic stem cell transplantation –an evolving treatment for severe autoimmune and inflammatory diseases in rheumatology, neurology and gastroenterology. Hematology12(3), 179–191 (2007).
   PubMed Web of Science ®Google Scholar
• Marmont AM. Immunoablation followed or not by hematopoietic stem cells as an intense therapy for severe autoimmune diseases. New perspectives, new problems. Haematologica86(4), 337–345 (2001).
   PubMed Web of Science ®Google Scholar
• Burt RK, Loh Y, Pearce W et al. Clinical applications of blood-derived and marrow-derived stem cells for nonmalignant diseases. JAMA299(8), 925–936 (2008).
   PubMed Web of Science ®Google Scholar
• Fortun PJ, Hawkey CJ. The role of stem cell transplantation in inflammatory bowel disease. Autoimmunity41(8), 654–659 (2008).
   PubMed Web of Science ®Google Scholar
• Oyama Y, Craig RM, Traynor AE et al. Autologous hematopoietic stem cell transplantation in patients with refractory Crohn’s disease. Gastroenterology128(3), 552–563 (2005).
   PubMed Web of Science ®Google Scholar
• Cassinotti A, Annaloro C, Ardizzone S et al. Autologous haematopoietic stem cell transplantation without CD34+ cell selection in refractory Crohn’s disease. Gut57(2), 211–217 (2008).
   PubMed Web of Science ®Google Scholar
• Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat. Rev. Immunol.8(9), 726–736 (2008).
   PubMed Web of Science ®Google Scholar
• Gonzalez-Rey E, Anderson P, González MA, Rico L, Büscher D, Delgado M. Human adult stem cells derived from adipose tissue protect against experimental colitis and sepsis. Gut58(7), 929–939 (2009).
   PubMed Web of Science ®Google Scholar
• González MA, Gonzalez-Rey E, Rico L, Büscher D, Delgado M. Adipose-derived mesenchymal stem cells alleviate experimental colitis by inhibiting inflammatory and autoimmune responses. Gastroenterology136(3), 978–989 (2009).
   PubMed Web of Science ®Google Scholar
• García-Olmo D, García-Arranz M, Herreros D, Pascual I, Peiro C, Rodríguez-Montes JA. A Phase I clinical trial of the treatment of Crohn’s fistula by adipose mesenchymal stem cell transplantation. Dis. Colon Rectum48(7), 1416–1423 (2005).
   PubMed Web of Science ®Google Scholar
• Kim JM, Rasmussen JP, Rudensky AY. Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. Nat. Immunol.8(2), 191–197 (2007).
   PubMed Web of Science ®Google Scholar
• Flores-Borja F, Jury EC, Mauri C, Ehrenstein MR. Defects in CTLA-4 are associated with abnormal regulatory T cell function in rheumatoid arthritis. Proc. Natl Acad. Sci. USA105(49), 19396–19401 (2008).
   PubMed Web of Science ®Google Scholar
• Lindley S, Dayan CM, Bishop A, Roep BO, Peakman M, Tree TI. Defective suppressor function in CD4(+)CD25(+) T-cells from patients with Type 1 diabetes. Diabetes54(1), 92–99 (2005).
   PubMed Web of Science ®Google Scholar
• Valencia X, Yarboro C, Illei G, Lipsky PE. Deficient CD4+CD25high T regulatory cell function in patients with active systemic lupus erythematosus. J. Immunol.178(4), 2579–2588 (2007).
   PubMed Web of Science ®Google Scholar
• Mottet C, Uhlig HH, Powrie F. Cutting edge, cure of colitis by CD4+CD25+ regulatory T cells. J. Immunol.170(8), 3939–3943 (2003).
   PubMed Web of Science ®Google Scholar
• Tang Q, Bluestone JA. Regulatory T-cell physiology and application to treat autoimmunity. Immunol. Rev.212(1), 217–237 (2006).
   PubMed Web of Science ®Google Scholar
• Tran DQ, Andersson J, Hardwick D, Bebris L, Illei GG, Shevach EM. Selective expression of latency associated peptide (LAP) and IL-1 receptor type I/II (CD121a/CD121b) on activated human FOXP3+ regulatory T cells allows for their purification from expansion cultures. Blood113(21), 5125–5133 (2009).
   PubMed Web of Science ®Google Scholar
• Barthlott T, Kassiotis G, Stockinger B. T cell regulation as a side effect of homeostasis and competition. J. Exp. Med.197(4), 451–460 (2003).
   PubMed Web of Science ®Google Scholar
• Pasare C, Medzhitov R. Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science299(5609), 1033–1036 (2003).
   PubMed Web of Science ®Google Scholar
• Suciu-Foca N, Berloco P, Cortesini R. Tolerogenic dendritic cells in cancer, transplantation, and autoimmune diseases. Hum. Immunol.70(5), 277–280 (2009).
   PubMed Web of Science ®Google Scholar
• Gonzalez-Rey E, Delgado M. Therapeutic treatment of experimental colitis with regulatory dendritic cells generated with vasoactive intestinal peptide. Gastroenterology131(6), 1799–1811 (2006).
   PubMed Web of Science ®Google Scholar